This trial is evaluating whether rTMS active treatment will improve 1 primary outcome and 10 secondary outcomes in patients with Alzheimer Disease. Measurement will happen over the course of Weeks 0 and 5.
This trial requires 200 total participants across 4 different treatment groups
This trial involves 4 different treatments. RTMS Active Treatment is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.
Results showed that subjects demonstrated improvement in cognitive complaints and activities of daily living. The rtms was superior to the placebo in the group's response to the treatment. A large, double-blind, placebo-controlled, randomized trial is warranted to verify these findings.
While both Alzheimer disease and vascular dementia are strongly associated with increased intracranial haemorrhage, the haemorrhagic stroke that occurs most often causes cerebral white matter lesions, whereas Alzheimer disease is mainly associated with a non-stroke 'diffuse' type of lesion. Other vascular diseases, e.g.
Alzheimer disease (AD) is a form of progressive neuronal degeneration with prominent clinical features including cognitive impairment, personality/behaviour changes, and functional decline. The exact cause for most cases of AD is currently unknown, but genetics and environmental factors are considered to play a role.
Although the cause and cure of AD are still unknown, even though a number of promising therapies have been developed to improve the symptoms, a cure for AD is yet to be found. However, one possible treatment exists that improves symptoms and slows down disease progression. The treatment option involves maintaining or increasing adherence to a Mediterranean diet.
About 1 in 7 elderly American men have dementia due to Alzheimer's disease annually. This figure is higher than in women because more women are diagnosed later than men, but still only make up 42% of Alzheimer's disease cases. About 200,000 US citizens have been diagnosed with at least one type of dementia in the past 4 years. In this decade, over 1 in 4 Americans over the age of 65 have dementia. In the US, about 10,000 people die from Alzheimer's disease each year.
There can be a variety of treatments for Alzheimer's disease. It is important to realize that not all treatment strategies are approved by the FDA. Most of the treatment guidelines are not completely evidence-based.
Signs of Alzheimer disease include mood swings, memory problems and behavioural changes. Although the exact cause of Alzheimer's disease cannot yet be determined, it appears some of these symptoms are reversible with treatment.\n
Given these clinical trials options, it is important to consider patients' willingness, capacity to participate, preferences and other specific clinical need, and the importance that patients place on their treatment decisions.
The frequency with which different treatment combinations for AD and PD were employed in the treatment trials did not reflect their use in clinical practice; however, most of the trials for these two diseases employed combinations that have been found to contribute to an overall benefit.
Rtl-treatment (and rtl-treatment in combination with huperzine-A) in Alzheimer's disease and rtms-treatment in schizophrenia may significantly reduce the number of depressive and positive symptoms of the diseases compared to placebo. The drugs may be also safe and non-toxic as compared to other used psychotrophics.
There is a lack of new discoveries specifically for Alzheimer's disease at this time and it seems we must rely on existing treatments for the disease in order to survive. Despite this, there are several promising therapies under development; it is important to remain aware of these new treatments as they may be important in the near future. New discoveries in Alzheimer's disease are extremely rare. The most frequently investigated treatments are those that help slow down the progression of the disease or improve symptoms; these include treatments that reduce beta amyloid plaque and treatments that help keep neurogenesis in place. New therapies are needed to help prevent the disease in the first place and also to treat it when it is already present. Many older therapeutics target amyloid beta plaques.
Currently, one of the most challenging decisions in therapeutic management of the elderly patient with cognitive impairment is the choice of the appropriate treatment. An integrated approach by combining pharmacological, cholinergic and noncholinergic treatment options has led to the development of a comprehensive treatment strategy, achieving a more effective and safer long-term outcome in patients with normal and impaired cognition.